rhfgf4 Search Results


rhfgf4  (Miltenyi Biotec)
93
Miltenyi Biotec rhfgf4
Rhfgf4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhfgf4/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
rhfgf4 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
blastoid medium tbm  (MedChemExpress)
97
MedChemExpress blastoid medium tbm
Blastoid Medium Tbm, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blastoid medium tbm/product/MedChemExpress
Average 97 stars, based on 1 article reviews
blastoid medium tbm - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
rhfgf4  (PeproTech)
90
PeproTech rhfgf4
Rhfgf4, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhfgf4/product/PeproTech
Average 90 stars, based on 1 article reviews
rhfgf4 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
recombinant human fgf4  (R&D Systems)
95
R&D Systems recombinant human fgf4
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fgf4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fgf4/product/R&D Systems
Average 95 stars, based on 1 article reviews
recombinant human fgf4 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
recombinant human fibrous growth factor-4 (rhfgf-4)  (PeproTech)
90
PeproTech recombinant human fibrous growth factor-4 (rhfgf-4)
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fibrous Growth Factor 4 (Rhfgf 4), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fibrous growth factor-4 (rhfgf-4)/product/PeproTech
Average 90 stars, based on 1 article reviews
recombinant human fibrous growth factor-4 (rhfgf-4) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
recombinant human fgf4 rhfgf4  (R&D Systems)
95
R&D Systems recombinant human fgf4 rhfgf4
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fgf4 Rhfgf4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fgf4 rhfgf4/product/R&D Systems
Average 95 stars, based on 1 article reviews
recombinant human fgf4 rhfgf4 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
recombinant human fibroblast growth factor  (R&D Systems)
95
R&D Systems recombinant human fibroblast growth factor
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fibroblast Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fibroblast growth factor/product/R&D Systems
Average 95 stars, based on 1 article reviews
recombinant human fibroblast growth factor - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
rhfgf4  (MedChemExpress)
95
MedChemExpress rhfgf4
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Rhfgf4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhfgf4/product/MedChemExpress
Average 95 stars, based on 1 article reviews
rhfgf4 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
recombinant human fgf 4  (R&D Systems)
91
R&D Systems recombinant human fgf 4
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fgf 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fgf 4/product/R&D Systems
Average 91 stars, based on 1 article reviews
recombinant human fgf 4 - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

Image Search Results


Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or Fgf4 treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.

Journal: Development (Cambridge, England)

Article Title: Atypical protein kinase C couples cell sorting with primitive endoderm maturation in the mouse blastocyst.

doi: 10.1242/dev.093922

Figure Lengend Snippet: Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or Fgf4 treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.

Article Snippet: Recombinant human FGF4 (rhFGF4, R&D Systems) was diluted at 500 ng/ml in KSOMAA in the presence of 1 μg/ml of heparin (Sigma) as described previously (Yamanaka et al., 2010).

Techniques: Control, Immunofluorescence

Fig. 7. Proposed model for PrE formation. ICM cells become primed towards a PrE or epiblast fate through the action of paracrine Fgf4. Sustained production of Fgf4 by epiblast precursors reinforces PrE fate, which is accompanied by aPKC enrichment in PrE precursors and upregulation of GATA4. aPKC would trigger survival signals in PrE cells that reach the ICM surface, which maintain their position. aPKC becomes polarised on the apical side of PrE cells at E4.5, when the PrE forms an epithelium.

Journal: Development (Cambridge, England)

Article Title: Atypical protein kinase C couples cell sorting with primitive endoderm maturation in the mouse blastocyst.

doi: 10.1242/dev.093922

Figure Lengend Snippet: Fig. 7. Proposed model for PrE formation. ICM cells become primed towards a PrE or epiblast fate through the action of paracrine Fgf4. Sustained production of Fgf4 by epiblast precursors reinforces PrE fate, which is accompanied by aPKC enrichment in PrE precursors and upregulation of GATA4. aPKC would trigger survival signals in PrE cells that reach the ICM surface, which maintain their position. aPKC becomes polarised on the apical side of PrE cells at E4.5, when the PrE forms an epithelium.

Article Snippet: Recombinant human FGF4 (rhFGF4, R&D Systems) was diluted at 500 ng/ml in KSOMAA in the presence of 1 μg/ml of heparin (Sigma) as described previously (Yamanaka et al., 2010).

Techniques: